Quinoxalinediones
CA 2281580 C · Owner: Pfizer Limited · Inventors: Stobie, Alan; Gautier, Elisabeth Colette Louise; Waite, David Charles
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides a substantially pure compound of formula (I), (see formula I) or a pharmaceutically acceptable salt or solvate thereof together with compositions containing, uses of processes, for the preparation of and intermediates used in the preparation of such compounds. The compounds are useful for treatment in a mammal of diseases by producing an antagonist effect at an NMDA receptor, for example acute neurodegenerative or chronic neurological disorders.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 24, 1998 and granted April 22, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 24, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 24, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.